Alliance Opposes Potential for PDAB Expansion in Maryland
Published February 5, 2025
The Alliance for Aging Research submitted a letter today opposing the proposed expansion of Prescription Drug Affordability Board (PDAB) in Maryland. The Alliance is concerned that SB357/HB424, which would enable the Maryland PDAB to set upper payment limits (UPLs) on prescription drugs that impact patients covered by commercial health plans, threatens to negatively impact the ability of patients to access critical medicines and further increase costs for Maryland taxpayers.
While the Alliance commends the Maryland General Assembly for its efforts to ensure patients can better access treatments they rely on, this bill to expand the authority of the PDAB has been introduced despite the board failing to deliver savings to patients in the form of lower out-of-pocket costs and incurring significant costs to taxpayers since its enactment.